Loading company
CNS Pharmaceuticals, Inc.
CNSP · Nasdaq · ·
$4.93-4.3%Sep 25 close
- 1M
- -10.7%
- 6M
- +117.2%
- 1Y
- -45.2%
- 5Y
- -100.0%
CNSP · Nasdaq · ·
$4.93-4.3%Sep 25 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$2.6M | -$2.4M | -8.97% |
| Profit per share | -$0.38 | -$2.67 | +85.77% |
| Free Cash Flow | -$3.5M | -$5.5M | +35.28% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
CNS Pharmaceuticals, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from CNS Pharmaceuticals, Inc.’s Item 2.02 8-K filed May 16, 2024; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.